Literature DB >> 32257755

A case of primary hepatic mucosa-associated lymphoid tissue lymphoma incidentally found in the sustained virological response state of chronic hepatitis C: review of the literature of this rare disease.

Tadahito Yasuda1, Shigeki Nakagawa1, Katsunori Imai1, Hirohisa Okabe1, Hiromitsu Hayashi1, Yo-Ichi Yamashita1, Akira Chikamoto1, Kazutaka Ozono2, Yoshiki Mikami2, Hideo Baba1.   

Abstract

A 54-year-old woman finished the treatment for chronic hepatitis C and achieved sustained virological response. She was identified with some tumor lesions at her liver during follow-up observation by ultrasonography. From contrast-enhanced computed tomography, there were four tumors at sub-segment 4/5, S5, S6, and S7. These lesions are slightly enhanced on arterial phase and washed out on delayed phase. Contrast-enhanced magnetic resonance imaging showed slight enhancement on arterial phase and defect on hepatocyte phase. Tumor markers including alpha fetoprotein, Des-Gamma-Carboxy Prothrombin, carcinoembryonic antigen, and carbohydrate antigen (CA19-9) were within normal range. The patient underwent partial hepatectomies of four tumors at S4/5, S5, S6, and S7. The patient was recovering well, so he discharged our hospital after 10 days from the operation. The histological assay of the resected specimen showed accumulation of lymphocyte with hyperplasia of lymphoid follicles accordant with tumor lesions. Immunohistochemical staining assay revealed a positive for CD3, CD20, CD10, and bcl-2. These findings eventually made a diagnosis of all four tumors as mucosa-associated lymphoid tissue lymphoma. Since previously published case reports and our case described nonspecific clinical features of this rare disease, it was difficult to get the certain diagnosis before histological confirmation and non-anatomical partial liver resection may be a good choice for both diagnosis and local therapy. © The Japan Society of Clinical Oncology 2020.

Entities:  

Keywords:  Hepatic MALT lymphoma; Liver hepatectomy; Sustained virological response state of chronic hepatitis C

Year:  2020        PMID: 32257755      PMCID: PMC7109212          DOI: 10.1007/s13691-019-00397-z

Source DB:  PubMed          Journal:  Int Cancer Conf J        ISSN: 2192-3183


  30 in total

1.  Hepatic mucosa-associated lymphoid tissue (MALT) lymphoma associated with hepatitis C.

Authors:  Shugo Mizuno; Shuji Isaji; Masami Tabata; Shinji Uemoto; Hiroshi Imai; Katsuya Shiraki
Journal:  J Hepatol       Date:  2002-12       Impact factor: 25.083

Review 2.  Primary hepatic marginal zone B cell lymphoma of mucosa-associated lymphoid tissue type: case report and review of the literature.

Authors:  Hirokazu Doi; Norio Horiike; Atsushi Hiraoka; Yohei Koizumi; Yasunori Yamamoto; Aki Hasebe; Soichi Ichikawa; Makoto Yano; Yasunao Miyamoto; Tomoyuki Ninomiya; Yoshihiro Ishimaru; Masao Miyagawa; Kazuhito Takamura; Hideki Kawasaki; Teruhiko Kozuka; Toshiharu Maeda; Tadashi Yoshino
Journal:  Int J Hematol       Date:  2008-09-23       Impact factor: 2.490

3.  Primary hepatic marginal zone lymphoma: A rare coincidence.

Authors:  Soumya Surath Panda; Manas Baisakh; Adyakinkar Panda; Hemlata Das
Journal:  Curr Probl Cancer       Date:  2018-01-08       Impact factor: 3.187

4.  Primary lymphoma of the liver: clinical-pathological features and relationship with HCV infection in French patients.

Authors:  Jean-Pierre Bronowicki; Catherine Bineau; Pierre Feugier; Olivier Hermine; Nicole Brousse; Frédéric Oberti; Marie-Christine Rousselet; Sébastien Dharancy; Philippe Gaulard; Jean-François Flejou; Dominique Cazals-Hatem; Eric Labouyrie
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

5.  Risk of Hepatocellular Cancer in HCV Patients Treated With Direct-Acting Antiviral Agents.

Authors:  Fasiha Kanwal; Jennifer Kramer; Steven M Asch; Maneerat Chayanupatkul; Yumei Cao; Hashem B El-Serag
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

Review 6.  Update on MALT lymphomas.

Authors:  Peter G Isaacson
Journal:  Best Pract Res Clin Haematol       Date:  2005-03       Impact factor: 3.020

Review 7.  Antiviral therapy of hepatitis C as curative treatment of indolent B-cell lymphoma.

Authors:  Michele Merli; Giuseppe Carli; Luca Arcaini; Carlo Visco
Journal:  World J Gastroenterol       Date:  2016-10-14       Impact factor: 5.742

8.  Antiviral Treatment of HCV-Infected Patients with B-Cell Non-Hodgkin Lymphoma: ANRS HC-13 Lympho-C Study.

Authors:  Laurent Alric; Caroline Besson; Nathanael Lapidus; Juliette Jeannel; Jean-Marie Michot; Patrice Cacoub; Danielle Canioni; Stanislas Pol; Frédéric Davi; Pascaline Rabiega; Loic Ysebaert; Delphine Bonnet; Olivier Hermine
Journal:  PLoS One       Date:  2016-10-17       Impact factor: 3.240

9.  Primary Hepatic Lymphoma Mimicking a Hepatocellular Carcinoma in a Cirrhotic Patient: Case Report and Systematic Review of the Literature.

Authors:  Ali Bohlok; Thierry De Grez; Fikri Bouazza; Roland De Wind; Melody El-Khoury; Deborah Repullo; Vincent Donckier
Journal:  Case Rep Surg       Date:  2018-04-10

10.  Primary non-Hodgkin lymphoma of liver.

Authors:  A Masood; S Kairouz; K H Hudhud; A Z Hegazi; A Banu; N C Gupta
Journal:  Curr Oncol       Date:  2009-08       Impact factor: 3.677

View more
  3 in total

1.  A case of primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma treated by radiofrequency ablation (RFA), and a literature review.

Authors:  Zhe Xu; Chong Pang; Jidong Sui; Zhenming Gao
Journal:  J Int Med Res       Date:  2021-03       Impact factor: 1.671

Review 2.  Primary hepatopancreatobiliary lymphoma: Pathogenesis, diagnosis, and management.

Authors:  Qianwen Wang; Kangze Wu; Xuzhao Zhang; Yang Liu; Zhouyi Sun; Shumei Wei; Bo Zhang
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

3.  Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection: Case Report and Summary of the Literature.

Authors:  Yuki Yamashita; Satoru Joshita; Hiroyuki Kobayashi; Shun-Ichi Wakabayashi; Ayumi Sugiura; Tomoo Yamazaki; Takeji Umemura
Journal:  Medicina (Kaunas)       Date:  2021-03-18       Impact factor: 2.430

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.